Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIntellipharmaceutics International Inc

Intellipharmaceutics International Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.08 CAD 0.00(0%)
Last update at 2024-04-08T13:30:00Z
Market Cap
2.15M

Momentum Score

…

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.08
Low
0.08
High
52 Week Price Range
0.04
Low
0.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.08
Dividend Yield
-
Revenue TTM
0.90M
Revenue Per Share
0.03
Gross Profit TTM
0.07M
Debt / Equity
-0.22
ROE
-
Net Debt
2.24M
ROCE
26.95%
Diluted EPS TTM
-0.12

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Type yearly yearly yearly yearly yearly
Date 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Income before tax -2.89M -5.26M -3.36M -8.09M -13.75M
Net income -2.89M -5.15M -3.39M -8.08M -13.74M
Selling general administrative 0.56M 1.25M 2.15M 4.17M 3.48M
Gross profit 0.07M 0.00M 1.40M 3.45M 1.59M
Reconciled depreciation 0.21M 0.26M 0.42M 0.51M 0.61M
Ebit -2.85M -4.17M -4.68M -7.83M -13.33M
Ebitda -2.64M -3.91M -1.76M -7.31M -12.89M
Depreciation and amortization 0.21M 0.26M 2.92M 0.52M 0.44M
Operating income -2.85M -4.17M -4.68M -7.83M -13.33M
Other operating expenses 2.92M 4.17M 6.08M 11.32M 15.04M
Interest expense 0.29M 0.55M 0.97M 0.25M 0.26M
Tax provision 0.01M -0.11M 0.03M -0.01M -
Interest income 0.08M 0.57M 1.14M 0.26M 0.42M
Net interest income -0.29M -0.55M -0.97M -0.23M -0.43M
Income tax expense 0.01M -0.11M 0.03M -0.01M -0.01M
Total revenue 0.07M 0.00M 1.40M 3.48M 1.71M
Total operating expenses 2.92M 4.17M 6.08M 11.28M 14.91M
Cost of revenue - 0.00M 0.00M 0.03M 0.12M
Total other income expense net -0.04M -1.09M 1.32M -0.26M -0.42M
Net income from continuing ops -2.89M -5.15M -3.39M -8.08M -13.75M
Net income applicable to common shares -2.89M -5.15M -3.39M -8.08M -13.75M
Breakdown 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Type yearly yearly yearly yearly yearly
Date 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Total assets 1.43M 2.10M 3.39M 3.80M 11.47M
Intangible assets - - - - 0.01M
Other current assets 0.02M - 0.12M 0.16M 0.59M
Total liab 12.01M 10.25M 9.70M 7.49M 7.37M
Total stockholder equity -10.58M -8.16M -6.31M -3.69M 4.10M
Other current liab 5.92M 4.55M 3.48M 1.83M 0.58M
Common stock 49.18M 49.18M 46.14M 45.56M 44.33M
Capital stock 49.18M 49.18M 46.14M 45.56M 44.33M
Retained earnings -105.13M -102.24M -97.10M -93.71M -85.62M
Other liab - - - - 2.06M
Other assets - - - - 0.00M
Cash 0.08M 0.77M 0.20M 0.06M 6.64M
Total current liabilities 12.01M 10.25M 9.70M 7.49M 5.31M
Current deferred revenue - - - - 0.30M
Net debt 2.24M 1.15M 1.91M 1.84M -4.85M
Short term debt 2.33M 1.92M 2.11M 1.90M 1.79M
Short long term debt 2.16M 1.92M 1.96M 1.90M 1.79M
Short long term debt total 2.33M 1.92M 2.11M 1.90M 1.79M
Other stockholder equity 45.10M 44.63M 44.35M 44.17M 45.11M
Property plant equipment 0.94M 0.99M 1.90M 2.27M 2.74M
Total current assets 0.49M 1.10M 1.48M 1.52M 8.72M
Net tangible assets -10.58M -8.16M -6.32M -3.70M 4.09M
Net receivables 0.39M 0.27M 1.05M 0.95M 1.24M
Inventory - 0.00M 0.11M 0.35M 0.25M
Accounts payable 3.76M 3.78M 4.10M 3.76M 2.64M
Accumulated other comprehensive income 0.28M 0.28M 0.28M 0.28M 0.28M
Common stock total equity - - 46.14M 45.56M 44.33M
Non currrent assets other - - - 2.27M 2.76M
Non current assets total 0.94M 0.99M 1.91M 2.27M 2.76M
Capital lease obligations 0.17M 0.00M 0.16M - -
Long term debt total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Type yearly yearly yearly yearly yearly
Date 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Investments 0.50M 0.00M 0.03M -0.01M -0.10M
Change to liabilities 1.34M 0.98M 2.03M 0.22M -0.56M
Total cashflows from investing activities 0.50M 0.50M 0.03M -0.01M -0.10M
Net borrowings 0.20M 0.20M 0.20M 0.07M 0.50M
Total cash from financing activities 0.20M 3.03M 3.03M 0.10M 17.35M
Change to operating activities -0.08M -0.10M 0.00M 0.43M -0.36M
Net income -2.89M -5.15M -3.39M -8.08M -13.75M
Change in cash -0.69M 0.57M 0.14M -6.58M 4.74M
Begin period cash flow 0.77M 0.20M 0.06M 6.64M 1.90M
End period cash flow 0.08M 0.77M 0.20M 0.06M 6.64M
Total cash from operating activities -1.39M -2.46M 0.11M -6.66M -12.51M
Issuance of capital stock 0.00M 3.07M 0.00M 0.00M 19.64M
Depreciation 0.21M 0.26M 0.42M 0.51M 0.61M
Other cashflows from investing activities 0.50M 0.00M 0.03M - -
Change to inventory - 0.00M 0.00M -0.10M -0.14M
Change to account receivables -0.00M 0.57M -0.39M 0.06M 0.45M
Sale purchase of stock 0.00M 3.07M 0.00M 0.03M 19.77M
Other cashflows from financing activities 0.50M -0.04M 0.03M 0.56M -2.29M
Change to netincome - 1.00M 1.41M 0.29M 1.23M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.10M
Change in working capital 1.27M 1.42M 1.68M 0.62M -0.60M
Stock based compensation -0.05M 0.01M 0.07M 0.26M 0.93M
Other non cash items 0.08M 1.08M 1.34M 0.04M 0.30M
Free cash flow -1.39M -2.46M 0.11M -6.68M -12.61M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IPCI
Intellipharmaceutics International Inc		 -
-%		 0.08 - - 2.38 - 5.09 -2.42
EPRX
Eupraxia Pharmaceuticals Inc		 0.03
0.31%		 9.68 - - - 8.45 - -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 - 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 4422.35 -6.36

Profile*

Intellipharmaceutics International Inc

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

30 Worcester Road, Toronto, ON, Canada, M9W 5X2

416 798 3001

https://www.intellipharmaceutics.com

11

Name Title Year Born
Dr. Isa Odidi MBA, Ph.D. Co-Founder, Chairman, CEO & Co-Chief Scientific Officer 1958
Dr. Amina Odidi Ph.D. Pres, COO, Co-Chief Scientific Officer, Acting CFO & Exec. Director 1960
Dr. Patrick N. Yat Ph.D. Vice-Pres of Chemistry & Analytical Services 1958
Fazayill Shaideen Controller NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 29.99
+13.13%
AP-UN
CAD 4.19
+12.94%
ARTG
CAD 39.66
+12.93%
BZ
CAD 4.14
+10.99%
FFH
CAD 2759.48
+10.87%
DRUG
CAD 27.12
-26.86%
HUT
CAD 69.10
-22.27%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.85
-14.43%
MOON
CAD 4.09
-12.79%

Equity Sectors*

  • Basic Materials

    +3.69%

  • Communication Services

    +2.61%

  • Consumer Cyclical

    +2.96%

  • Consumer Defensive

    +1.11%

  • Energy

    -5.01%

  • Financial Services

    +2.20%

  • Healthcare

    -0.56%

  • Industrials

    -0.73%

  • Real Estate

    +1.90%

  • Technology

    +0.05%

  • Utilities

    +1.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…